Biolevox™ HA ONE is a hyaluronic acid (HA) gel, especially designed for a single intra-articular injection in order to ameliorate symptoms of the osteoarthritis (OA) in synovial joint.

HA-based gel product contains 120 mg of hyaluronate in 4.8 mL pre-filled syringe. A unique combination of optimally high molecular weight and high concentration of hyaluronate in Biolevox™ HA ONE creates a gel characterized with optimally high viscosity and elasticity1. Thus, Biolevox™ HA ONE stands as an ideal solution for a single shot viscosupplementation therapy as it provides a very high dose of optimally high molecular hyaluronate in single injection.

As a result, upon the injection, Biolevox HA ONE is able to effectively lubricate cartilaginous surfaces and absorb the shocks that occur during movement of OA affected joint in which synovial fluid properties have been highly compromised2.

Unquestionably, Biolevox™ HA ONE due to its unique physicochemical properties is able to ameliorate OA symptoms like pain and joint mobility limitation and thus significantly improve OA patient’s quality of life3.

Viscosupplementation, so intra-articular injection of HA, is scientifically and clinically approved practice for reducing joint pain, improving functional condition of OA-affected joint, finally delaying the progression of the disease¹.
Importantly, treatment based on the single intra-articular injection of HA demonstrate a therapeutic effectiveness and significant improvement of the OA symptoms leading to recovery of patient’s quality of life².

{|blog_list|}

Biolevox™ HA ONE contains a very high dose of 120 mg sodium hyaluronate in a single injection of 4.8 mL volume. The therapy is dedicated as an one injection because the gel in characterized with the optimal 2.5% concentration of hyaluronate that provides precisely selected viscosity, tailored in the range of 250-400 Pa*s. Hyaluronate contained in Biolevox™ HA ONE is characterized with optimally high molecular weight of molecules that stays in the range of 1.2 to 3.2 MDa.

HA-based gel with such a unique properties improves shock absorption and lubrication of the cartilaginous surfaces as well as reduces inflammation state due to appropriate biological response via CD44 receptors. Moreover, such content are particularly tailored for a single intra-articular HA treatment, providing long term clinical effect in OA patients^3,4.

Therapy based on Biolevox™ HA ONE is perfectly safe as hyaluronan contained in the product is manufactured in fully controllable conditions by bacterial fermentation with use of Streptococcus sp. strain., providing the products that possess no possibility for uncontrolled tissue response upon the intra-articular injection^3,5.

The administration of Biolevox™ HA ONE is recommended as single intra-articular therapy. Clinical data show that single intra-articular injection of hyaluronic acid gel with appropriately selected properties like one of Biolevox™ HA ONE is clinically effective in ameliorating OA symptoms for at least 6 months⁶.

Package of Biolevox™ HA ONE contains single pre-filled syringe of 4.8 ml

The product is meant to use by medical practitioners only.

Hyaluronic acid (HA) is one of the major constituent of articular cartilage extracellular matrix and synovial fluid¹. HA is a biopolysacharide- it consists of a number of sugar molecules bonded together into a long chain¹.

HA is a crucial structural component of synovial joint as it acts as a lubricant, shock absorber, filler and metabolic agent². OA development diminishes lubricating and shock absorption abilities of synovial fluid mainly by degradation of naturally produced HA³.

Viscosupplementation, so intra-articular injection of HA, is scientifically and clinically approved practice for reducing joint pain, improving functional condition of OA-affected joint, protecting cartilage and finally delaying progression of the disease⁴.

{|blog_list|}

Intra-articular injection of HA restores and maintains viscoelastic properties of synovial fluid, thus enables improved lubrication and reliefs pain⁵. HA exerts anti-inflammatory, analgesic and chondroprotective effects in synovial joints⁶. In long term, clinical benefits of viscosupplementation persist well beyond the intraarticular residence of HA since clinical benefits achieved by HA intra-articular injection occurs due to increase of naturally produced HA in synovial joint thus reestablishment of joint homeostasis3. In consequence, viscosupplementation can improve joint function, thus allow return to normal physical activity and improve patients quality of life⁷.

Importantly, many scientific comparisons and clinical investigations show that intra-articular HA injection is comprehensively safe, in contrast to steroid intra-articular injection that can lead to cartilage thinning and damage⁸.